ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference Transcript
© -
Welcome, everyone, to the 31st Annual Healthcare Conference. I'm Tiago Fauth, Biotech Analyst here at Credit Suisse. We're joined today by ALX Oncology. Sophia Randolph, CMO of the company. We're going to do a presentation with 5 to 10 minutes Q&A at the end of the presentation. So Sophia taking away.
Thank you. So as we just said, I'm Sophia Randolph, I'm Chief Medical Officer here at ALX, and happy to give you an update on our program. Here are disclaimers. So here at ALX, we're working on advancing a very differentiated pipeline. And our lead molecule is evorpacept, which is a CD47 innate system checkpoint inhibitor.
Evorpacept is designed to really unleash the full immune response against the patient's cancer. So it exclusively inhibits CD47 as a myeloid checkpoint inhibitor, but does not target CD47 as a cancer-specific antigen. And because of that, we can
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
